| Oct 31 |
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen’s Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer
|
| Oct 21 |
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
|
| Oct 14 |
Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit
|
| Oct 1 |
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum
|
| Sep 11 |
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
|
| Sep 10 |
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer
|
| Sep 3 |
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
|
| Sep 3 |
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 30 |
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice
|
| Aug 28 |
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
|
